Enoblituzumab, previously known as TJ-271 or MGA271, represents an innovative monoclonal targeting CD33, an antigen found predominantly on cancer tissues. This molecule works as a dual-action molecule, concurrently https://lewysknii497816.blog5.net/92503267/enoblituzumab-a-deep-dive-into-tj-271-and-mga271